Abbott EVP Louis Morrone sells 5,850 shares

Abbott Laboratories executive Louis H. Morrone, Executive Vice President, reported transactions in common shares.

Rhea-AI Filing Summary

Abbott Laboratories executive Louis H. Morrone, Executive Vice President, reported transactions in common shares. On August 11, 2026, he sold 5,850 common shares in a non-derivative transaction at $109.83 per share, leaving 70,724 common shares held directly. On August 12, 2026, a discretionary transaction under Rule 16b-3(f) disposed of 12 indirectly held shares in a Profit Sharing Trust at $107.99 per share, leaving no shares reported under that indirect ownership.

Insider Trade Summary

Net Seller: 5,850 shares

Net Sell 2 txns

Insider Morrone Louis H.

Role EXECUTIVE VICE PRESIDENT

Sold 5,850 shs ($643K)

Type	Security	Shares	Price	Value
Discretionary	Common shares without par value	12	$107.99	$1K
Sale	Common shares without par value	5,850	$109.83	$643K

Holdings After Transaction: Common shares without par value — 70,724 shares (Direct); Common shares without par value — 0 shares (Indirect, Profit Sharing Trust)

Key Figures

Shares sold: 5,850 shares Sale price per share: $109.83 per share Shares following transaction: 70,724 shares +2 more

5 metrics

Shares sold 5,850 shares Non-derivative sale on August 11, 2026

Sale price per share $109.83 per share Price for 5,850-share sale on August 11, 2026

Shares following transaction 70,724 shares Directly held common shares after August 11, 2026 sale

Discretionary transaction shares 12 shares Discretionary transaction under Rule 16b-3(f) on August 12, 2026

Discretionary transaction price $107.99 per share Price for 12-share discretionary transaction via Profit Sharing Trust

Key Terms

Rule 16b-3(f), Profit Sharing Trust, non-derivative

3 terms

Rule 16b-3(f) regulatory

"A discretionary transaction under Rule 16b-3(f) disposed of 12 indirectly held shares"

Profit Sharing Trust financial

"a discretionary transaction under Rule 16b-3(f) disposed of 12 indirectly held shares in a Profit Sharing Trust"

non-derivative financial

"sold 5,850 common shares in a non-derivative transaction at $109.83 per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ABBOTT LABORATORIES (ABT) report for Louis H. Morrone?

ABBOTT LABORATORIES reported that Executive Vice President Louis H. Morrone sold and disposed of common shares. He sold 5,850 shares on August 11, 2026, and a Profit Sharing Trust disposed of 12 indirectly held shares on August 12, 2026.

How many ABBOTT LABORATORIES (ABT) shares did Louis H. Morrone sell and at what prices?

Louis H. Morrone sold 5,850 common shares at $109.83 per share on August 11, 2026. A separate discretionary transaction disposed of 12 shares at $107.99 per share on August 12, 2026.

How many ABBOTT LABORATORIES (ABT) shares does Louis H. Morrone hold after these transactions?

After the reported transactions, Louis H. Morrone directly holds 70,724 common shares of ABBOTT LABORATORIES. The Profit Sharing Trust’s indirectly held position decreased by 12 shares to zero reported shares following the discretionary transaction.

Were Louis H. Morrone’s ABBOTT LABORATORIES (ABT) trades under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as an affirming plan (aff_10b5_one is false). One transaction is identified as a discretionary transaction under Rule 16b-3(f), but no Rule 10b5-1 trading plan is affirmed.

What type of ABBOTT LABORATORIES (ABT) security did Louis H. Morrone trade?

Both reported transactions involve ABBOTT LABORATORIES common shares without par value. One transaction was a sale in open market or private transaction, and the other was a discretionary transaction under Rule 16b-3(f) through a Profit Sharing Trust.

What does the discretionary ABBOTT LABORATORIES (ABT) transaction under Rule 16b-3(f) involve?

The discretionary transaction under Rule 16b-3(f) on August 12, 2026, reflects the disposition of 12 common shares held indirectly in a Profit Sharing Trust at $107.99 per share, reducing that indirect holding to zero.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2026 - 05:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morrone Louis H.

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXECUTIVE VICE PRESIDENT

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	08/11/2026		S		5,850	D	$109.83	70,724	D
Common shares without par value	08/12/2026	08/13/2026	I		12	D	$107.99	0	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Louis H. Morrone by Jessica H. Paik, Attorney-in-Fact	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)